Cardiovascular diseases

  • Email
  • Help

This page brings together the European Medicines Agency's latest information on diseases affecting the heart and blood vessels.

It lists:

  • the ten newest and recently updated medicines authorised for the treatment of cardiovascular diseases in the European Union (EU);
  • the most recent opinions on cardiovascular medicines that are pending authorisation by the European Commission (EC);
  • the latest news and press releases related to cardiovascular diseases;
  • the Agency's events on cardiovascular topics.

Opinions pending EC decision



  • 12/06/2017 - 13/06/2017


    EMA/FDA/Health Canada joint workshop addressing unmet needs of children with pulmonary arterial hypertension

    This joint workshop organised the European Medicines Agency (EMA), the United States Food and Drug Administration (FDA) and Health Canada brings together experts and stakeholders to discuss requirements for the development of medicines in paediatric pulmonary arterial hypertension (PAH) and to address the need of the current paediatric clinical practice in a timely manner. The objectives are to improve the understanding of problems related to the conduct of clinical trials in the paediatric population, refine endpoints and study design to address the clinical trials challenges in this rare paediatric population, set priorities in future research in the field of pharmacokinetics and pharmacodynamics measurements and post-marketing tools in paediatric PAH medicines and provide medicine developers with more guidance specific to global product development which takes into account current limitations. ... Read more